Novartis announced that it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with...
Novartis announced that it has completed its divestment of ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to $2.5 billion, consisting of $1.75 billion in upfront cash plus potential additional milestone payments
Novartis announced that it has signed an agreement to divest ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to $2.5 billion, including $1.75 billion in upfront cash, plus additional milestone payments.
RegeneRx Biopharmaceutical announced that a new study was published comparing RGN 259 (thymosin beta 4) with currently approved prescription products...